Please join us to discuss the indications for PARP inhibitors for ovarian cancer, including maintenance versus treatment. We will explore the role of bevacizumab in ovarian cancer treatment, including platinum sensitive and resistant disease and maintenance. We will delve deeper into novel therapeutics for ovarian cancer, including immunotherapy and antibody drug conjugates.

JOINT ACCREDITATION

In support of improving patient care, Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit designation Statement – Physicians This activity is approved for 1.5  AMA PRA Category 1 Credits ™

ANCC Credit Designation Statement- Nurse This activity is approved for 1.5 ANCC contact hours.

This activity has not been submitted to ACPE for Pharmacist credit.

PA's may claim maximum of 1.5 AMA PRA Category 1™ credits for completing this activity.

Series Information
Date Presented:
February 15, 2018 6:00 PM Central
Length:
1 hour, 30 minutes
Registration Fee:
Free
Cocktail - Targeted Treatment for Ovarian Cancer
Speaker Information
Debra Richardson MD  [ view bio ]
Individual topic purchase: Selected
ACCME
AMA PRA Category 1 Credit(s)™: 1.50
Products
Streaming
SGO Member Price:$0.00
Non-Member Price:$0.00